Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Agilent Technologies, Inc. $A

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 57,475 shares of the medical research company’s stock, valued at approximately $7,634,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Core Wealth Advisors LLC acquired a new position in Agilent Technologies during the 4th quarter worth about $26,000. SHP Wealth Management acquired a new position in Agilent Technologies in the 4th quarter valued at about $26,000. Navalign LLC purchased a new stake in Agilent Technologies during the fourth quarter worth about $27,000. Cedar Mountain Advisors LLC purchased a new stake in Agilent Technologies during the first quarter worth about $27,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Agilent Technologies during the fourth quarter worth about $28,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on A shares. Wells Fargo & Company dropped their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Wolfe Research reiterated a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Jefferies Financial Group began coverage on shares of Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price target for the company. HSBC cut their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Barclays increased their price objective on Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $160.24.

Agilent Technologies Stock Up 0.3%

Shares of NYSE:A opened at $155.16 on Thursday. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $160.51. The firm’s 50 day moving average price is $139.16 and its 200 day moving average price is $126.65. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The stock has a market cap of $43.82 billion, a price-to-earnings ratio of 31.16, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.84 billion. During the same quarter in the previous year, the business posted $1.37 EPS. The firm’s revenue was up 8.1% on a year-over-year basis. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, equities research analysts predict that Agilent Technologies, Inc. will post 6.05 earnings per share for the current fiscal year.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and ahead of the roughly $1.84 billion consensus estimate. Adjusted EPS of $1.62 exceeded estimates near $1.48-$1.49 and rose from $1.37 a year earlier. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability and cash generation strengthened. Operating profit increased 23.3% to $444 million, operating cash flow rose 43.4% to $519 million, and the company ended the quarter with $1.8 billion in cash. GAAP net income reached $362 million, or $1.28 per diluted share, versus $336 million, or $1.18, a year earlier. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Agilent raised fiscal 2026 adjusted EPS guidance to $6.18-$6.21, above the approximately $6.06 consensus, and projected revenue of about $7.5 billion versus expectations near $7.4 billion. Management cited improving laboratory-tools demand. Fourth-quarter guidance was broadly in line with analyst estimates. Agilent Raises Annual Profit Forecast
• Neutral Sentiment: Institutional investor positioning was mixed: 594 investors increased holdings in the latest quarter, while 550 reduced positions. Recent analyst targets have a median of $155, suggesting limited near-term upside relative to the recent trading level.
• Negative Sentiment: Despite the earnings beat, Agilent trades at a relatively demanding valuation, with a P/E ratio above 31, and the stock is close to its 12-month high. This could make the shares more sensitive to any slowdown in laboratory-equipment demand or future guidance disappointments.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.